Arkolith/Insider Trading/NAMS/Form 4

Davidson Michael H.

Chief Executive Officer, DirectorNewAmsterdam Pharma Co N.V. (NAMS) · full profile →Form 4 · filed Mar 2, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$14.8M
Net Open-Market Flow
-$14.8M
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 2, 2026Sell(S)444K$33.25$14.8M174K
Mar 2, 2026Option exercise(M)444K——618K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 2, 2026Option exercise(M)444K—$0239K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-085947) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML